Drug Profile
Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture/St. Jude Children's Research Hospital
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator St. Jude Childrens Research Hospital
- Developer Eisai Co Ltd; Medicines for Malaria Venture; St. Jude Childrens Research Hospital
- Class Isoquinolines; Small molecules
- Mechanism of Action Calcium-transporting ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malaria
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Malaria in USA (PO)
- 30 May 2017 Eisai and Charles River Laboratories extend collaboration to develop next-generation anti-malaria therapeutics
- 15 Feb 2016 Eisai Co Ltd and Charles River Laboratories collaborate to develop Malaria therapeutics